These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16030027)

  • 1. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
    Banerjee S; Smith IE; Folkerd L; Iqbal J; Barker P; Dowsett M;
    Ann Oncol; 2005 Oct; 16(10):1632-8. PubMed ID: 16030027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
    BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
    Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Hozumi Y; Suemasu K; Takei H; Aihara T; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Ann Oncol; 2011 Aug; 22(8):1777-82. PubMed ID: 21285133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
    Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
    Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
    Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
    Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
    Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
    Sestak I; Harvie M; Howell A; Forbes JF; Dowsett M; Cuzick J
    Breast Cancer Res Treat; 2012 Jul; 134(2):727-34. PubMed ID: 22588672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
    Yang Y; Pan W; Tang X; Wu S; Sun X
    Oncotarget; 2017 Jul; 8(29):48362-48374. PubMed ID: 28415634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.